Ads
related to: moderna covid-19 vaccine (spikevax)
Search results
Moderna’s sales from its only product, the COVID-19 vaccine, fell 91% from last year
Fortune via AOL· 6 days agoIn the first quarter of the year, Moderna reported $167 million in sales of its only product on the...
Is Moderna Stock A Buy On Its Eye-Popping First-Quarter Sales Beat?
Investor's Business Daily· 5 hours agoNeither metric lines up with investing advice...stocks with recent earnings and sales growth of 20%...
Moderna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025...
Benzinga via Yahoo Finance· 6 days agoThursday, Moderna Inc (NASDAQ:MRNA) reported a first-quarter EPS loss of $(3.07), down from an...
Moderna stock surges 15% after it beat earnings expectations despite plummeting COVID vaccine sales
Quartz· 6 days agoModerna stock soared on Thursday after its first-quarter earnings report sailed past Wall Street’s...
Moderna COVID vaccine sales plummet 91 percent - The Boston Globe
The Boston Globe· 6 days agoSales of Moderna’s COVID-19 vaccine plunged 91 percent from the previous year for the first quarter...
Moderna posts quarterly sales beat, smaller loss than expected
Reuters via Yahoo Finance· 6 days ago(Reuters) -Moderna on Thursday reported quarterly revenue that beat Wall Street estimates but came...
Moderna expects CDC to view its RSV vaccine as equal to rival shots
Reuters· 6 days ago, opens new tab said on Thursday it expects U.S. Center for Disease Control and Prevention (CDC)...
Decoding Moderna Inc (MRNA): A Strategic SWOT Insight
GuruFocus.com via Yahoo Finance· 5 days agoStrengths Robust mRNA Technology Platform: Moderna Inc (NASDAQ:MRNA) has established a strong...
Moderna Swings to 1Q Loss, But Sees Data on New Vaccine Later in '24
Market Watch· 6 days agoModerna swung to a hefty first-quarter loss but the maker of Covid 19 vaccines forecast some seasonal strength in ...
Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates
Morningstar· 6 days agoReports first quarter revenues of $167 million, GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)Prepares for launches of RSV vaccine and Spikevax< ...
